331 related articles for article (PubMed ID: 24975284)
1. Safely targeting cancer stem cells via selective catenin coactivator antagonism.
Lenz HJ; Kahn M
Cancer Sci; 2014 Sep; 105(9):1087-92. PubMed ID: 24975284
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
Gang EJ; Hsieh YT; Pham J; Zhao Y; Nguyen C; Huantes S; Park E; Naing K; Klemm L; Swaminathan S; Conway EM; Pelus LM; Crispino J; Mullighan CG; McMillan M; Müschen M; Kahn M; Kim YM
Oncogene; 2014 Apr; 33(17):2169-78. PubMed ID: 23728349
[TBL] [Abstract][Full Text] [Related]
3. Sam68 Allows Selective Targeting of Human Cancer Stem Cells.
Benoit YD; Mitchell RR; Risueño RM; Orlando L; Tanasijevic B; Boyd AL; Aslostovar L; Salci KR; Shapovalova Z; Russell J; Eguchi M; Golubeva D; Graham M; Xenocostas A; Trus MR; Foley R; Leber B; Collins TJ; Bhatia M
Cell Chem Biol; 2017 Jul; 24(7):833-844.e9. PubMed ID: 28648376
[TBL] [Abstract][Full Text] [Related]
4. CBP/Catenin antagonists: Targeting LSCs' Achilles heel.
Kim YM; Gang EJ; Kahn M
Exp Hematol; 2017 Aug; 52():1-11. PubMed ID: 28479420
[TBL] [Abstract][Full Text] [Related]
5. Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer.
Kartha VK; Alamoud KA; Sadykov K; Nguyen BC; Laroche F; Feng H; Lee J; Pai SI; Varelas X; Egloff AM; Snyder-Cappione JE; Belkina AC; Bais MV; Monti S; Kukuruzinska MA
Genome Med; 2018 Jul; 10(1):54. PubMed ID: 30029671
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
Zhao Y; Wu K; Wu Y; Melendez E; Smbatyan G; Massiello D; Kahn M
Curr Mol Pharmacol; 2018; 11(2):113-121. PubMed ID: 28933312
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Human Airway Epithelial Tissue Stem Cell Differentiation by β-Catenin, P300, and CBP.
Malleske DT; Hayes D; Lallier SW; Hill CL; Reynolds SD
Stem Cells; 2018 Dec; 36(12):1905-1916. PubMed ID: 30171668
[TBL] [Abstract][Full Text] [Related]
8. The β-catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner.
Wiese M; Walther N; Diederichs C; Schill F; Monecke S; Salinas G; Sturm D; Pfister SM; Dressel R; Johnsen SA; Kramm CM
Oncotarget; 2017 Apr; 8(16):27300-27313. PubMed ID: 28460484
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic targeting of CBP/β-catenin signaling reduces cancer stem-like population and synergistically suppresses growth of EBV-positive nasopharyngeal carcinoma cells with cisplatin.
Chan KC; Chan LS; Ip JC; Lo C; Yip TT; Ngan RK; Wong RN; Lo KW; Ng WT; Lee AW; Tsao GS; Kahn M; Lung ML; Mak NK
Sci Rep; 2015 Apr; 5():9979. PubMed ID: 25897700
[TBL] [Abstract][Full Text] [Related]
10. CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells.
Zhao Y; Masiello D; McMillian M; Nguyen C; Wu Y; Melendez E; Smbatyan G; Kida A; He Y; Teo JL; Kahn M
Oncogene; 2016 Jul; 35(28):3705-17. PubMed ID: 26657156
[TBL] [Abstract][Full Text] [Related]
11. Disruption of β-catenin/CBP signaling inhibits human airway epithelial-mesenchymal transition and repair.
Moheimani F; Roth HM; Cross J; Reid AT; Shaheen F; Warner SM; Hirota JA; Kicic A; Hallstrand TS; Kahn M; Stick SM; Hansbro PM; Hackett TL; Knight DA
Int J Biochem Cell Biol; 2015 Nov; 68():59-69. PubMed ID: 26315281
[TBL] [Abstract][Full Text] [Related]
12. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
[TBL] [Abstract][Full Text] [Related]
13. Kat3 coactivators in somatic stem cells and cancer stem cells: biological roles, evolution, and pharmacologic manipulation.
Thomas PD; Kahn M
Cell Biol Toxicol; 2016 Feb; 32(1):61-81. PubMed ID: 27008332
[TBL] [Abstract][Full Text] [Related]
14. E7386, a Selective Inhibitor of the Interaction between β-Catenin and CBP, Exerts Antitumor Activity in Tumor Models with Activated Canonical Wnt Signaling.
Yamada K; Hori Y; Inoue S; Yamamoto Y; Iso K; Kamiyama H; Yamaguchi A; Kimura T; Uesugi M; Ito J; Matsuki M; Nakamoto K; Harada H; Yoneda N; Takemura A; Kushida I; Wakayama N; Kubara K; Kato Y; Semba T; Yokoi A; Matsukura M; Odagami T; Iwata M; Tsuruoka A; Uenaka T; Matsui J; Matsushima T; Nomoto K; Kouji H; Owa T; Funahashi Y; Ozawa Y
Cancer Res; 2021 Feb; 81(4):1052-1062. PubMed ID: 33408116
[TBL] [Abstract][Full Text] [Related]
15. Chronic chemotherapeutic stress promotes evolution of stemness and WNT/beta-catenin signaling in colorectal cancer cells: implications for clinical use of WNT-signaling inhibitors.
Ayadi M; Bouygues A; Ouaret D; Ferrand N; Chouaib S; Thiery JP; Muchardt C; Sabbah M; Larsen AK
Oncotarget; 2015 Jul; 6(21):18518-33. PubMed ID: 26041882
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of CREB binding protein-beta-catenin signaling down regulates CD133 expression and activates PP2A-PTEN signaling in tumor initiating liver cancer cells.
Tang Y; Berlind J; Mavila N
Cell Commun Signal; 2018 Mar; 16(1):9. PubMed ID: 29530069
[TBL] [Abstract][Full Text] [Related]
17. Wnt Signaling in Stem Cells and Cancer Stem Cells: A Tale of Two Coactivators.
Kahn M
Prog Mol Biol Transl Sci; 2018 Jan; 153():209-244. PubMed ID: 29389517
[TBL] [Abstract][Full Text] [Related]
18. The Small-Molecule Wnt Inhibitor ICG-001 Efficiently Inhibits Colorectal Cancer Stemness and Metastasis by Suppressing MEIS1 Expression.
Choi JH; Jang TY; Jeon SE; Kim JH; Lee CJ; Yun HJ; Jung JY; Park SY; Nam JS
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948208
[TBL] [Abstract][Full Text] [Related]
19. In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis.
Li Y; Xiao Y; Lin HP; Reichel D; Bae Y; Lee EY; Jiang Y; Huang X; Yang C; Wang Z
Biomaterials; 2019 Jan; 188():160-172. PubMed ID: 30352320
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
